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ABSTRACT
Vitamin K (vitamin K1 or phylloquinone and vitamin K2, a series of menaquinones [MKs]) is involved in the production of bone andmatrix
amino acid g-carboxy-glutamic acid (Gla) proteins, regulating bone and vascular calcification. Low vitamin K concentrations are
associated with increased risks of fractures and vascular calcification, and frequent complications in hemodialysis patients. We carried
out an observational study to establish the prevalence of vitamin K deficiency and to assess the relationship between vitamin K status,
vertebral fractures, vascular calcification, and survival in 387 patients on hemodialysis for 1 year. We determined plasma levels of
vitamin K compound, bone-Gla-protein, matrix-Gla-protein, and routine biochemistry. Vertebral fractures (reduction in vertebral body
height by 20%) and aortic and iliac calcifications were also investigated in a spine (D5–L4) radiograph. Three-year patient survival was
analyzed. Important proportions of patients had deficiency of MK7 (35.4%), vitamin K1 (23.5%), and MK4 (14.5%). A total of 55.3% of
patients had vertebral fractures, 80.6% had abdominal aorta calcification, and 56.1% had iliac calcification. Vitamin K1 deficiency was the
strongest predictor of vertebral fractures (odds ratio [OR], 2.94; 95% confidence interval [CI], 1.38–6.26). MK4 deficiency was a predictor of
aortic calcification (OR, 2.82; 95% CI, 1.14–7.01), whereas MK5 deficiency actually protected against it (OR, 0.38; 95% CI, 0.15–0.95). MK7
deficiency was a predictor of iliac calcification (OR, 1.64; 95% CI, 1.03–2.60). The presence of vertebral fractures was also a predictor of
vascular calcifications (OR, 1.76; 95% CI, 1.00–3.08). Increased alkaline phosphatase and C reactive protein (CRP), age, and cerebrovascular
events were predictors of mortality. Our study suggests that the vitamin K system may be important for preserving bone mass and
avoiding vascular calcification in hemodialysis patients, pointing out a possible role of vitamin K in bone and vascular health. Based on
our results, we suggest that the general population should also be studied for vitamin K deficiency as a possible cause of both vertebral
fractures and vascular calcification.  2012 American Society for Bone and Mineral Research.
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Introduction
Vitamin K includes a series of 2-methyl-1,4-naphthoquinonederivatives: vitamin K1 (phylloquinone), which occurs
naturally in food, mainly green leafy vegetables and fruits
(avocado, kiwi), and vitamin K2; ie, several menaquinones (MKs),
which are mainly synthesized by bacteria in the intestinal tract
and occur in cheese, meat, and fermented soya derivatives.
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Because very little vitamin K is stored, it needs to be continually
replenished.(1)
Vitamin K acts as the coenzyme of a carboxylase that
determines carboxylation of glutamic acid residues, resulting in
the formation of the amino acid g-carboxy-glutamic acid (Gla).
In the liver this reaction controls the production of coagulation
factors, whereas in extrahepatic tissues vitamin K controls also
the production of bone and matrix Gla proteins (BGP and MGP).
BGP is a small protein produced by osteoblasts under the
control of vitamin D, which modulates the expression of its
gene. It contains three GLA residues that enable its binding to
hydroxyapatite in bone.(2) BGP knockout mice develop hyperos-
tosis, showing that it has a role in promoting normal bone
mineralization.(3) Vitamin K deficiency in bone can be measured
indirectly by measuring uncarboxylated BGP (ucBGP). MGP is
a larger protein produced by osteoclasts, chondrocytes and
vascular smooth muscle cells (VSMC), which is a potent inhibitor
of arterial calcification.(4) MGP knockout mice experience
pathological fractures due to severe osteoporosis and wide-
spread vascular calcification.(5) MGP undergoes not only vitamin
K-dependent g-glutamate carboxylation, which determines its
bioactivity as calcification inhibitor, but also serine phosphoryla-
tion. Thus, there are two possible states: an extracellular
phosphorylated fraction and a nonphosphorylated fraction
inside matrix vesicles or apoptotic bodies, implying that
nonphosphorylated MGP may predict local VSMC stress.(4)
In chronic kidney disease (CKD) mineral and bone disorder is
very common and associated with major adverse outcomes:
in CKD patients the risk of hip fracture is four times higher than in
the general population and the Dialysis Outcomes and Practice
Patterns (DOPPS) study conducted in 12 countries in 2002 to
2004 reported an incidence of 8.9 new hip fractures and of 25.6
new fractures of any kind per 1000 patient-years.(6,7) Another
common disorder in CKD patients is vascular calcification.
The prevalence of calcification of the aorta is twice as high as in
the general population and vascular calcifications have been
found to be associated with a higher prevalence of vertebral
fractures.(8) The pathogenesis of vascular calcification in CKD
patients is multifactorial, and phosphate overload is probably
one of the most relevant inducing factors.(9) In fact, inorganic
phosphate induces arterial calcification directly through a real
‘‘ossification’’ of the arterial tunica media, and control of serum
phosphate in CKD patients is crucial in preventing vascular
calcification. Calcification inhibitors are also important determi-
nants of vascular calcification,(10) and the vitamin K-dependent
MGP is one of the most relevant of them.
What is more, in women on hemodialysis, both severe vascular
calcifications and vertebral fractures are risk factors for mortality
(RR¼ 3.2 and 4.8, respectively).(8) Aortic calcification is also
associated with osteoporotic fractures in the general popula-
tion.(11)
Low intake of vitamin K1 has recently been associated with
an increase in the risk of hip fracture in the general population,
and treatment with vitamin K may reduce the relative risk for
nonvertebral and hip fractures.(12,13) Moreover, consumption
of natto, a local Japanese food rich in vitamin K, is associated
with significantly higher bone mineral density (BMD) in elderly
Japanese men, and high dietary intake of vitamin K is associated
with higher BMD in elderly subjects of both genders.(14,15)
Conversely, low dietary vitamin K intake is associated with low
BMD in women of all ages.(16) Few studies have investigated the
role of vitamin K in cardiovascular disease. In the Rotterdam
study high dietary intake of vitamin K2 was associated with
a reduction in the risk not only of severe aortic calcification
(odds ratio [OR], 0.48; 95% confidence interval [CI], 0.32–0.71),
but also of the relative risk of CHD mortality (OR, 0.43; 95% CI,
0.24–0.77).(17)
We carried out an observational study, with follow-up to assess
vital status, primarily to assess the prevalence of deficiency of
vitamin K1 and vitamin K2 (menaquinones) in dialysis patients.
The secondary objectives were to assess the impact of vitamin K
status on vitamin K–dependent proteins related to bone
turnover, vertebral fractures, vascular calcification, and survival.
Patients and Methods
This was an observational study conducted at 18 dialysis centers
in Italy. All the local ethics committees approved the study, which
was conducted according to the regulations in force related to
observational studies. Approval dates ranged from July 14, 2008
to October 26, 2009. Patient enrollment took place between
November 2008 and November 2009, and follow-up to assess
vital status was performed in December 2011.
Patient population
We included adult patients of both genders who had been on
hemodialysis for more than 1 year, provided that they gave their
informed consent in writing to the use of their medical records
for the study.
We excluded patients who had a life expectancy of less than
6 months, who had any evidence of cancer (with the exception
of basalioma), who had coagulation disorders, or who had any
condition that, according to the investigator, could interfere with
the outcome of the study.
Healthy controls (n¼ 62) were blood donors matched by age
(56.8 3.9; range, 51–65 years) and gender (males: 43 [69.4%];
females: 19 [30.6%]) to dialysis patients. They were recruited on a
voluntary basis during the study period.
Procedures
We collected the following information: demographic data
(initials or ID number, gender, age); renal failure history
(cause, type of hemodialysis, duration of hemodialysis in
months, transplantation history); lifestyle (smoking status,
alcohol consumption); medical history; and body mass index
(BMI).
We drew venous blood samples when the patients were
fasting for the determination of serum concentrations of vitamin
25(OH)D, vitamin K components: osteocalcin (bone Gla Protein,
or BGP) and matrix Gla protein (MGP), routine biochemistry,
including in particular total alkaline phosphatase (ALP), albumin,
C-reactive protein (CRP), aluminum, and lipid profile. The
Laboratory in Perugia determined vitamin K components
by a simple, sensitive, and selective reversed-phase high-
performance liquid chromatography (HPLC) method, developed
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for the simultaneous determination of vitamin K in human
plasma. Clear and well-separated chromatographic PK and MKs
profiles were obtained in healthy human and uremic plasma.
Uremic plasma is characterized by an increased level of plasma
lipids and lipoproteins, which are interfering factors to
chromatography. Thus, we adopted a liquid-liquid extraction
and then a solid-phase extraction of human plasma using
Polymeric Reversed Phase cartridges, achieving a good
reproducibility. The vitamers were measured by an electrochem-
ical detector after postcolumn reduction with platinum on
alumina powder and using the MK8 form as internal standard.
Quantitative recovery was obtained in a range of 80% to 96% for
PK and MK vitamers. Vitamin K values were corrected according
to triglyceride levels.(18) The Laboratory in Padua determined the
following: total 25-OH vitamin D and total BGP using the LIASON
25 OH Vitamin D and Osteocalcin Assays 310600 and 310950
(DiaSorin, Inc., Stillwater, MN, USA); undercarboxylated osteo-
calcin (uc-OC) using the Glu-OC EIA Kit MK118 (Takara Bio, Inc.,
Otsu, Shiga, Japan), MGP using the Human MGP–Matrix GLA
Protein Kit (Biomedica Medizinprodukte GmbH & Co KG, Wien,
Austria); and undercarboxylated MGP using by the method
provided by VitaK BV (Maastricht, The Netherlands).(19) The other
parameters were determined according to standard laboratory
methods.
We obtained a radiograph of the thoracic and lumbar regions
of the spinal column (D5–L4) in the latero-lateral view with
the patient in the lateral recumbent position. The following
recommendations were made: the X-ray was always to be
performed by the same technician using the same film distance
(100 cm) and the same focus for the central ray, namely D7 for
the dorsal region and L3 for the lumbar region. The radiographs
were sent to CNR for blinded evaluation in duplicate.
We considered a vertebral fracture to be present when the
height of the vertebral body was reduced by at least 20% (4mm),
according to Genant and colleagues(20) and Guglielmi and
colleagues.(21)
We quantified vascular calcifications by measuring the length
of calcific deposits along the anterior and posterior wall of the
aorta (mild 0.1–5 cm, moderate 5.1–10 cm, and severe >10 cm).
This methodology has been used and validated by previous
publications.(22) With a similar approach, we also determined
the presence or absence of calcifications of the iliac arteries in
the same radiograph (mild 0.1–3 cm, moderate 3.1–5 cm, and
severe >5 cm).
We followed patients for survival for a mean period of
2.7 0.5 years.
Statistical analysis
We determined the sample size to study the prevalence of
vitamin K deficiency. Based on the finding of a prevalence of 24%
setting a vitamin K cutoff of 0.5 nmol/L in Framingham’s study in
the general population and of 29% in 142 hemodialysis patients,
we assumed that the prevalence of vitamin K deficiency would
be about 30% and that therefore 400 patients would be needed
to achieve a 95% CI of 4.(23,24)
We defined vitamin K deficiency considering the values
included between the 5th and the 95th percentile of the
distribution of healthy control subjects as normal reference
values.(25)
We conducted the identification of any predictors of vertebral
fractures (model a) or vascular calcification (model b) using
univariate logistic regression. Any significant predictors with
p 0.20 were introduced into a multivariate model using the
stepwise selection method. In the multiple regression models
we included variables that met criteria to be confounders
(ie, variables that were related to both the exposure [vitamin K
deficiency] and to study outcomes), which were not an effect of
exposure and which were not in the causal pathway between the
exposure and the study outcomes,(26) as well as all univariate
correlates of study outcomes. For quantitative variables, linearity
assumption was evaluated considering the analysis of quartiles.
Possible interactions among predictors were also assessed. OR
and corresponding 95% CI were calculated for each variable.
We checked the vital status of patients through a follow-up
telephone interview. The differential distribution of ALP, CRP,
MGP (total, undercarboxylated [uc]), BGP (total, undercarboxy-
lated [uc]), vitamin K deficiency, and aortic and iliac calcifications
between survivors and nonsurvivors was analyzed by x2 or
Fisher’s exact test, or the Wilcoxon rank sum test. Survival curves
to determine the association of mortality and aortic or iliac
calcifications were estimated using Kaplan-Meier analyses; the
log-rank test was also performed. Cox proportional hazards
models were defined with outcome overall mortality, and the
assumption of proportionality was assessed through the analysis
of Schoenfeld residuals of the covariates introduced in the
model. Hazard ratio (HR) and 95% CIs were calculated.
We performed all statistical analyses using the SAS statistical
package (version 9.2, SAS Institute, Inc., Cary, NC, USA).
Results
A total of 387 adult patients and 62 healthy controls were
included. The patients were mainly men (63%). Substantial
proportions of patients had cardiovascular risk factors, such as
hypertension (78.6%) and diabetes mellitus (22%). Some patients
were suffering from concomitant diseases that could interfere
with vitamin K status (liver disease 14%, malabsorption
syndrome 1%). A minority had a history of fractures (6.7%
before dialysis, 10.4% after) (Table 1).
The serum concentrations of phylloquinone (PK) and the
various menaquinones (MK) components of vitamin K2 are
shown in Table 2. Important proportions of patients had
deficiency of MK7 (35.4%), PK (23.5%), and MK4 (14.5%). The
distribution of the most deficient component, MK7, is shown in
Fig. 1A and B. All the subgroups of patients with vitamin K
component deficiency had significant increases in triglycerides
ranging from 26% to 59.8% (p< 0  0001 except MK6, p¼ 0.004).
The comparison between dialysis patients and healthy
controls (Table 3) disclosed a number of significant differences:
in dialysis patients ucBGP was 11-fold higher and total BGP was
12-fold higher, whereas ucMGP was threefold lower and total
MGP was more than twice as high. In addition, the median
vitamin D level was lower by 27.5% in dialysis patients. There
were no differences in total and/or ucBGP and/or MGP between
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Table 1. Main Characteristics of the Study Cohort
Parameter Study cohort (n¼ 387)
Age (years), mean SD (range) 64.2 14.1 (18–89)
Gender, n (%)
Males 244 (63.0)
Females 143 (37.0)
BMI (kg/m2), mean SD 25.1 4.4
Type of dialysis, n (%)
Bicarbonate 189 (48.7)
Hemodiafiltration 102 (26.4)
Acetate free biofiltration 54 (14.0)
Hemofiltration 32 (8.3)
Other 10 (2.6)
Smoking (both smokers and ex-smokers) 136 (36.8)
Alcohol drinkers (active and former) 82 (22.7)a
Diabetes mellitus 85 (22.0)
Arterial hypertension 304 (78.6)
Angina 64 (16.5)
Myocardial infarction 73 (18.9)
Atrial fibrillation 51 (13.2)
Heart failure 39 (10.1)
Peripheral arterial disease 134 (34.6)
Cerebrovascular events [stroke] 41 (10.6) [20 (5.2)]
Parathyroidectomy 26 (6.7)
Fractures before dialysis 26 (6.7)
After dialysis 40 (10.4)
Malabsorption syndrome 4 (1.0)
Liver disease 54 (14.0)
Values are n (%), mean SD, or mean SD (range).
BMI¼body mass index.
aData on alcohol consumption available for 361 patients.
Table 2. Vitamin K Status in 387 Adult Patients on Dialysis and 62 Healthy Controls
Vitamers
Healthy controls Dialysis patients
Literature(22)
normal range
Patients with
deficiency (%)Mean SD Median Range Mean SD Median Range
PK (Vit K1) 1.36 1.08 1.13 0.14–4.06 0.98 1.00 0.63 0.03–5.12 0.17–3.05 11.1
Adjusted PKa 1.80 1.77 1.26 0.11–7.22 0.70 0.80 0.43 0.01–5.07 0.21–6.23 23.5
MK4 0.91 0.85 0.84 0.03–3.42 0.67 0.74 0.51 0.01–4.86 0.07–2.68 8.8
Adjusted MK4a 1.20 1.28 0.75 0.06–5.23 0.51 0.67 0.37 0.01–5.19 0.06–4.39 14.5
MK5 1.29 1.12 1.13 0.09–5.12 1.00 0.77 1.00 0.02–4.99 0.10–3.07 2.8
Adjusted MK5a 1.56 1.35 1.40 0.08–5.95 0.75 0.66 0.75 0.01–5.52 0.10–3.79 7.8
MK6 1.10 1.14 0.73 0.04–5.09 0.63 0.67 0.48 0-01–4.79 0.04–3.33 3.6
Adjusted MK6a 1.26 1.30 0.62 0.05–5.43 0.47 0.59 0.34 0.003–5.31 0.05–3.87 9.6
MK7 1.95 1.37 1.43 0.22–4.82 1.15 1.01 1.09 0.02–5.15 0.33–4.48 18.1
Adjusted MK7a 2.53 2.19 1.93 0.23–9.46 0.87 0.95 0.70 0.004–8.89 0.44–6.46 35.4
The vitamers concentrations are expressed in ng/mL. Vitamin K deficiency was defined considering the values included between the 5th and the
95th percentile of the healthy control subjects distribution as normal reference values.(22)
MK¼menaquinone; PK¼ phylloquinone.
aAdjusted for triglycerides.
Fig. 1. Distribution of plasma levels of MK7, the vitamer which showed
the most remarkable deficiency. Concentrations are expressed in ng/mL.
(A) Unadjusted. (B) adjusted for triglycerides levels.
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patients with and without vitamin K deficiency, except for the
patients with vitamin K1 deficiency, who had significantly lower
median ucBGP (8.7 versus 11.7 ng/mL, p¼ 0.01) and significantly
higher ucMGP (683 versus 519.5 nmol/L, p¼ 0.03), and patients
with MK6 deficiency, who had significantly higher total median
MGP (22.5 versus 17.9 nmol/L, p¼ 0.01).
More than one-half of the patients (55.3%) had vertebral
fractures. The comparison between patients with and without
vertebral fractures suggested that the presence of vertebral
fractures was associated with vitamin K1 deficiency (15.4%
versus 5.8%, p< 0.01) (Table 4), but not with MKs. This was
confirmed by logistic regression, which identified vitamin K1
deficiency as the strongest predictor of vertebral fractures
that increased the probability threefold (OR, 2.94). In contrast,
albumin was a protective factor: an increase by 1 g/dL was
associated with a 40% reduction in the probability of fracture
(OR, 0.6) (Table 4).
Most patients had vascular calcification: 80.6% had calcifica-
tion of the abdominal aorta, which was moderate in 29.7% and
severe in 30%, and 56.1% had iliac calcification, which was
moderate in 29.7% and severe in 14%. Only 16.5% of patients did
not have any vascular calcification and more than one-half the
patients (53.2%) had calcification of both the abdominal aorta
and the iliac arteries.
The proportion of patients with MK4 deficiency was
significantly higher among the patients with aortic calcification
(10.6% versus 1.3%, p¼ 0.01). On the contrary, MK5 deficiency
was significantly lower (6.4% versus 13.3%, p¼ 0.04). Logistic
regression showed that MK4 deficiency was a predictor that
increased the probability of aortic calcification threefold,
whereas MK5 deficiency actually protected against it, reducing
the probability by 67% (Table 5). Among the patients with iliac
calcifications the proportion of patients with MK7 deficiency was
significantly higher than in those without (41% versus 28.2%,
p¼ 0.009) and logistic regression showed that MK7 deficiency
is a predictor of iliac calcification (OR, 1.61), together with age
(OR, 1.86), atrial fibrillation (OR, 3.10), and vertebral fractures
(OR, 2.10) (Table 6). MK4/triglyceride deficiency and vertebral
fractures were found to be predictors of calcification of both the
abdominal aorta and the iliac arteries (OR, 3.99; 95% CI, 1.23–
12.93, and OR, 2.80; 95% CI, 1.46–5.37, respectively).
A total of 77 patients died during follow-up (19.9%). Mean
follow-up amounted to 2.7 0.5 years. Most patients died of
cardiovascular events (n¼ 51); other causes were infections
(n¼ 11), cancer (n¼ 5), and miscellaneous (n¼ 10). Aortic and
iliac calcifications were more common in nonsurvivors (90.9%
versus 78.1%, p¼ 0.01, and 66.2% versus 53.6%, p¼ 0.04,
respectively); the differences were more pronounced when
only severe calcifications were considered (48.1% versus 25.5%,
p¼ 0.0001; 23.4% versus 11.6%, p< 0.01). The course of survival
probability of patients with and without severe aortic calcifica-
tions is shown in Fig. 2. There were no significant differences in
vitamin K1 or MKs between nonsurvivors and survivors. The
same was true for other laboratory variables, except for median
alkaline phosphatase (ALP) and C reactive protein (CRP), which
were significantly higher in nonsurvivors (99.0 versus 80.0 pg/dL,
p¼ 0.0002; 1.85 versus 1.54mg/L, p¼ 0.03) and median MGP,
which was significantly lower (15.0 versus 19.7 nmol/L, p¼ 0.02).
Nonsurvivors had more vertebral fractures (62.3% versus 53.6%,
Table 3. Healthy Controls Versus Dialysis Patients
Variables
Healthy
controls
(n¼ 62)
CKD
patients
(n¼ 387) p
25-OH-D (ng/mL) <0.0001
Median 40.0 29.0
25th percentile 36.2 27.2
75th percentile 44.5 31.5
Total BGP (mg/L) <0.0001
Median 15.3 182
25th percentile 12.8 96.3
75th percentile 18.2 318.8
ucBGP (ng/mL) <0.0001
Median 0.88 11.00
25th percentile 0.54 4.62
75th percentile 1.60 17.20
Total MGP (nmol/L) <0.0001
Median 8.0 18.8
25th percentile 7.0 12.7
75th percentile 9.0 30.9
ucMGP (nmol/L) <0.0001
Median 1682.9 569.0
25th percentile 1286.00 288.0
75th percentile 2147.5 933.0
BGP¼ bone Gla protein; CKD¼ chronic kidney disease; MGP ¼Gla
protein; uc¼ undercarboxylated.
Table 4. Logistic Regression With the Presence of Vertebral
Fractures as Outcome
Odds ratio 95% CI p
Sex (male) 1.75 1.13–2.69 0.0118
Age 67 years 1.80 1.18–2.76 0.0064
Vitamin K1 deficiency 2.94 1.38–6.26 0.0053
Albumin (g/dL) 0.60 0.38–0.94 0.0264
Steroid therapy 2.41 0.89–6.54 0.0840
CI¼ confidence interval.
Table 5. Logistic Regression With the Presence of Abdominal
Aortic Calcification as Outcome
Odds ratio 95% CI p
Age (years) 1.05 1.03–1.07 <0.0001
Arterial hypertension 2.00 1.07–3.75 0.0307
Myocardial infarction 2.78 1.10–7.05 0.0310
Vertebral fractures 1.81 1.03–3.18 0.0389
MK4/triglycerides deficiency 2.82 1.13–7.05 0.0266
MK5/triglycerides deficiency 0.33 0.13–0.85 0.0217
CI¼ confidence interval.
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p¼ 0.16) and lower ucMGP levels (477 versus 584 ng/mL,
p¼ 0.14). ALP and CRP were predictors of mortality (Table 7).
Discussion
In this observational study substantial proportions of hemodial-
ysis patients had deficiency of vitamin K compounds (up to 35%),
vertebral fractures (55%), and vascular calcification (aortic
calcification 80%, iliac calcification 56%). Vitamin K compound
deficiency was found to be a predictor of both vertebral fractures
and vascular calcification. Mortality was associated with lower
MGP and higher ALP levels.
To our knowledge, this is the first study that provides a
comprehensive assessment of vitamin K status, including most
vitamin K vitamers; ie, phylloquinone (PK) and menaquinones
(MK4, MK5, MK6, and MK7), adjusting their values for
triglycerides levels. Previously, only vitamin K1 levels were
measured in the few large studies that assessed vitamin K
deficiency.(18,23,24) These studies found that vitamin K1 deficien-
cy amounted to 24% in the general population and to 29% in
hemodialysis patients,(23,24) which is consistent with our finding
of a rate of 23.5% vitamin K1 deficiency. Vitamin K2 has several
different vitamers: MK7 is better known and often the only one
considered, but others, such as MK4, MK5, and MK6, may
have important biologic actions. Moreover, the adjustment
for triglyceride concentration is particularly relevant for the
assessment of vitamin K status. Vitamin K components are all
liposoluble compounds that become part of chylomicrons after
absorption from the gut and as such are transported to the liver.
Vitamin K1 remains partly in the liver, whereas vitamin K2 is
transferred to VLDL and LDL for transport and there is close
correlation (r¼ 0.99) between triglyceride concentrations and
vitamin K1.(1,18)
Previous publications reported that vitamin K1 had no
effect on bone mineral density or bone markers of skeletal
turnover.(27,28) However, in both cases an association with a
reduced incidence of fractures was found for a low dietary
vitamin K intake(27) and for warfarin-induced vitamin K deficit.(28)
This is the first study to relate vitamin K1 and K2 deficiency
directly both to vertebral fractures and vascular calcification.
Vitamin K1 deficiency was the strongest predictor of vertebral
fractures. This is consistent with the findings of Cheung and
colleagues,(29) who found that 5mg vitamin K1 protected
postmenopausal women from fractures, despite a lack of effect
on BMD and bone resorption. It is also consistent with the
findings of Nakano and colleagues,(13) who found that plasma
concentrations of vitamin K1 and albumin were significant
determinants of hip fracture in the general population, whereas
MK-7 was not. Indeed, our results show that satisfactory albumin
status protects against vertebral fractures (OR, 0.60), whereas
MK7 does not. These findings are also supported by the outcome
of the Hordaland Health Study,(12) in which low dietary intake of
vitamin K1, but not of vitamin K2, was associated with hip
fracture in 2800 Norwegian subjects, monitored for 10 years.
The other important result was that MK4 deficiency is a
predictor of aortic calcification in humans. This finding, reported
for the first time in humans, is consistent with the experimental
suggestion that MK4 acts as an inhibitor of vascular calcification
in the vessel wall, based on the downregulation of osteopro-
tegerin gene expression and osteoprotegerin protein secretion
from MK4-treated cells.(30)
MK7 was not a predictor of aortic calcification, whereas it was a
predictor of iliac artery calcifications (OR, 1.61). The different
effect of menaquinones on different vascular compartments can
not be explained with the available data. Our findings need to
be confirmed and expended by further studies. Similarly and
surprisingly, MK5 deficiency appeared to be protective against
aortic calcification (OR, 0.33). To our knowledge this is the first
time that deficiency of a component of the vitamin K2 system
is found to actually be protective against vascular calcification.
The fact that two MKs appear to exert opposite effects suggests
that vitamin K2 should not be studied as a single entity.
Table 6. Logistic Regression With the Presence of Iliac Calcifi-
cation as Outcome
Odds ratio 95% CI p
Age 67 years 1.86 1.21–2.87 0.0048
Triglycerides (>206mg/dL) 1.67 1.00–2.79 0.0521
Atrial fibrillation 3.10 1.49–6.42 0.0024
Vertebral fractures 2.10 1.67–3.22 0.0007
MK7/triglycerides deficiency 1.61 1.02–2.54 0.0426
CI¼ confidence interval.
Fig. 2. Survival curves in patients with severe aortic calcifications (dotted
line) and in all the remaining patients (without calcifications or with mild
to moderate calcification, log rank test p< 0.0001).
Table 7. Logistic Regression With Mortality as Outcome
HR 95% CI p
Age (increase by 1 year) 1.047 1.024–1.070 <0.0001
CRP (increase by 1 Unit) 1.029 1.017–1.042 <0.0001
ALP (increase by 10 Units) 1.049 1.012–1.082 0.0056
Cerebrovascular event 1.917 1.046–3.515 0.0354
Angina 1.602 0.943–2.723 0.0813
ALP¼ alkaline phosphatase; CI¼ confidence interval; CRP¼C reactive
protein; HR¼ hazard ratio.
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Findings reported in Table 3 also need to be mentioned. We
confirmed that 25(OH)-vitamin-D levels in CKD patients are lower
than healthy control and the same applies to ucMGP levels.
Accordingly, Cranenburg and colleagues(19) have highlighted
in four different patient populations (patients who underwent
angioplasty, patients with aortic stenosis, hemodialysis patients,
and calciphylaxis patients) significantly lower circulating ucMGP
levels in comparison with healthy controls. In particular, in the
hemodialysis and calciphylaxis populations, virtually all subjects
had ucMGP levels below the normal adult range. On the other
hand, dialysis patients in our study showed higher levels of total
MGP, total BGP, and ucBGP. However, total MGP, including
active, calcification-inhibiting carboxylated MGP, was lower in
the subgroup of nonsurvivors. Recently, Schlieper and collea-
gues(31) reported that dephosphorylated, carboxylated MGP
levels are lower in dialysis patients than in normal subjects, with
an increased risk of all-cause (HR, 2.2) and cardiovascular
mortality (HR, 2.7). Our finding of lower total MGP in the
subgroup of nonsurvivors is similar. However, we did not
measure dephosphorylated, carboxylated MGP levels. The
increased levels of total MGP are also a noteworthy finding,
as it can not be considered a marker of calcification. The finding,
in patients with vitamin K1 deficiency, of significantly lower
ucBGP and significantly higher ucMGP, as well as, in patients with
MK6 deficiency, of significantly higher total MGP is contradictory
and needs to be confirmed by further studies.
Another significant finding was that ALP increase is a predictor
of mortality. The association between high ALP andmortality has
already been reported in dialysis patients.(32) We did notmeasure
the ALP bone isoenzyme, but only total ALP. This could
determine an influence of liver impairment to the results
obtained in our study. However, liver disease was among the
variables considered in our study (54 patients, 14%; see Table 1),
but it was associated neither with K2 vitamers nor with bone
biochemical data.
The main limitation of this study is its observational design.
The prognostic impact of a condition, such as vitamin K
deficiency, is difficult to study with an experimental design.
Nevertheless, the possibility of potential bias or imprecision in
data collection should be kept in mind.
At present, guidelines for CKD patients do not make any
particular recommendations regarding vitamin K.(33) In view of
the potential consequences of vitamin K–deficiency vertebral
fractures, which are associated with higher mortality, and
vascular calcification, which is a risk factor for cardiovascular
morbidity and mortality, we believe that adequate intake of
vitamin K, together with calcium and vitamin D, should be
recommended. The addition may preserve bone calcification
and avoid harmful vascular calcification in CKD patients. The
recommendations should be formulated in terms of intake of
both vitamin K1 and MKs, namely MK4 and MK7 and not vitamin
K2 in general or just MK7. At present, no recommendations can
be made about vitamin K supplements, an issue that needs to
be clarified in randomized controlled trials.
Moreover, we suspect that the role of vitamin K deficiency in
bone and vascular disease may not be confined to CKD patients.
Calcium supplements (with or without vitamin D) have been
found to increase the risk of cardiovascular events in
postmenopausal patients.(34) Additional studies should be
performed to investigate the role of vitamin K in bone fractures
and vascular calcification in the general population.
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